EQRx, based in Cambridge, Mass., will gain exclusive rights to G1’s lerociclib in the United States, Europe, Japan and all other global markets, excluding the Asia-Pacific region (except Japan).
Read More
G1 Therapeutics has landed a licensing del worth up to $310 million not counting royalties for a breast cancer treatment it currently has under development.
Read More
G1 Therapeutics has landed a deal with a China-based company to license an oncology drug. The deal could be worth as much as $46 million.
Read More
G1 Therapeutics Inc. reported a fourth-quarter loss lower than Wall Street expectations according to a Securities and Exchange filing on Thursday.
Read More
The drug, trilaciclib, achieved both of its primary endpoints: reductions in the duration and occurrence of Grade 4 neutropenia, a low count of neutrophils, a type of white blood cell.
Read More
Research Triangle Park-based clinical-stage biopharmaceutical company G1 Therapeutics has reported more positive results for its investigational oncology drug, trilaciclib.
Read MoreThe chair of G1 Therapeutics Inc., a Durham-based biopharmaceutical company, recently sold 10,000 of the company’s shares for a net gain of $493,310, according to a securities filing.
Read More
Clinical oncology company G1 Therapeutics Inc. is raising $180 million to advance its drug development programs by selling 3 million shares of common stock in a secondary stock offering.
Read MoreA group of venture capital investors have sold $38.4 million worth of stock in G1 Therapeutics.
Read More
